A phase I/II clinical trial of GTB-3550 (CD16/IL-15/CD33) TriKE is currently ongoing for the treatment of MDS, refractory/relapsed AML or advanced systemic mastocytosis. The gene discussed is CD33; the disease is myelodysplastic syndrome.